{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:41:39Z","timestamp":1753180899469,"version":"3.41.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Innovation Foundation of Dalian","award":["2024JJ13PT069","2024JJ13PT069"],"award-info":[{"award-number":["2024JJ13PT069","2024JJ13PT069"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02612-1","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:23:33Z","timestamp":1747754613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of a clinical prediction model for sensitivity to combination therapy of Bcl-2 inhibitors and hypomethylating agents in elderly\/unfit patients with acute myeloid leukemia"],"prefix":"10.1007","volume":"16","author":[{"given":"Yufeng","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"issue":"10393","key":"2612_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401(10393):2073\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(23)00108-3.","journal-title":"Lancet"},{"key":"2612_CR2","unstructured":"Acute Myeloid Leukemia-Cancer Stat Facts. SEER. https:\/\/seer.cancer.gov\/statf-acts\/html\/amyl.html."},{"issue":"2","key":"2612_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41. https:\/\/doi.org\/10.1038\/s41408-021-00425-3.","journal-title":"Blood Cancer J"},{"issue":"12","key":"2612_CR4","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Sur-veillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127(12):2049\u201361. https:\/\/doi.org\/10.1002\/cncr.33458.","journal-title":"Cancer"},{"issue":"6","key":"2612_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cncr.22496","volume":"109","author":"AK Burnett","year":"2007","unstructured":"Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114\u201324. https:\/\/doi.org\/10.1002\/cncr.22496.","journal-title":"Cancer"},{"issue":"2","key":"2612_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3324\/haematol.2018.208637","volume":"105","author":"C Talati","year":"2020","unstructured":"Talati C, Dhulipala VC, Extermann MT, Ali NA, Kim J, Komrokji R, et al. Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia. Haematologica. 2020;105(2):398\u2013406. https:\/\/doi.org\/10.3324\/haematol.2018.208637.","journal-title":"Haematologica"},{"issue":"3","key":"2612_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291\u20139. https:\/\/doi.org\/10.1182\/blood-2015-01-621664.","journal-title":"Blood"},{"issue":"21","key":"2612_CR8","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670\u20137. https:\/\/doi.org\/10.1200\/JCO.2011.38.9429.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2612_CR9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers14030826","volume":"14","author":"M Dargenio","year":"2022","unstructured":"Dargenio M, Tarantini G, Cascavilla N, Pavone E, Musto P, Mazza P, et al. Long-term follow-up of elderly patients with acute myeloid leukemia treated with decitabine: a real world study of the apulian hematological network. Cancers (Basel). 2022;14(3):826. https:\/\/doi.org\/10.3390\/cancers14030826.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2612_CR10","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1080\/10428194.2021.2022140","volume":"63","author":"N Gadaud","year":"2022","unstructured":"Gadaud N, Leroy H, B\u00e9rard E, Tavitian S, Leguay T, Dimicoli-Salazar S, et al. Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study. Leuk Lymphoma. 2022;63(6):1398\u2013406. https:\/\/doi.org\/10.1080\/10428194.2021.2022140.","journal-title":"Leuk Lymphoma"},{"key":"2612_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/ijms19020448","volume":"19","author":"CM Pfeffer","year":"2018","unstructured":"Pfeffer CM, Singh ATK. Apoptosis: a target for anticancer therapy. Int J Mol Sci. 2018;19:448. https:\/\/doi.org\/10.3390\/ijms19020448.","journal-title":"Int J Mol Sci"},{"key":"2612_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3389\/fonc.2019.00192","volume":"9","author":"A McBride","year":"2019","unstructured":"McBride A, Houtmann S, Wilde L, Vigil C, Eischen CM, Kasner M, et al. The role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome. Front Oncol. 2019;9:192. https:\/\/doi.org\/10.3389\/fonc.2019.00192.","journal-title":"Front Oncol"},{"issue":"1","key":"2612_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/hematology.2020000154","volume":"2020","author":"AW Roberts","year":"2020","unstructured":"Roberts AW. Therapeutic development and current uses of BCL-2 inhibition. Hematology Am Soc Hematol Educ Program. 2020;2020(1):1\u20139. https:\/\/doi.org\/10.1182\/hematology.2020000154.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2612_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u20138. https:\/\/doi.org\/10.1038\/nm.3048.","journal-title":"Nat Med"},{"issue":"10","key":"2612_CR15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a Phase II Study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106\u201317. https:\/\/doi.org\/10.1158\/2159-8290.","journal-title":"Cancer Discov"},{"issue":"1","key":"2612_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752.","journal-title":"Blood"},{"issue":"7","key":"2612_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"issue":"11","key":"2612_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791\u2013803. https:\/\/doi.org\/10.1182\/blood.2019003988.","journal-title":"Blood"},{"issue":"14","key":"2612_CR19","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1080\/10428194.2021.1973675","volume":"62","author":"S Venugopal","year":"2021","unstructured":"Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, et al. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma. 2021;62(14):3501\u20135. https:\/\/doi.org\/10.1080\/10428194.2021.1973675.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2612_CR20","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404\u20137. https:\/\/doi.org\/10.3324\/haematol.2018.188094.","journal-title":"Haematologica"},{"issue":"10","key":"2612_CR21","doi-asserted-by":"publisher","first-page":"E253","DOI":"10.1002\/ajh.25567","volume":"94","author":"I Aldoss","year":"2019","unstructured":"Aldoss I, Yang D, Pillai R, Sanchez JF, Mei M, Aribi A, et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Am J Hematol. 2019;94(10):E253\u20135. https:\/\/doi.org\/10.1002\/ajh.25567.","journal-title":"Am J Hematol"},{"issue":"7","key":"2612_CR22","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/cancers14071734","volume":"14","author":"J Labrador","year":"2022","unstructured":"Labrador J, Saiz-Rodr\u00edguez M, de Miguel D, de Laiglesia A, Rodr\u00edguez-Medina C, Vidriales MB, et al. Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: The PETHEMA Registry experience. Cancers (Basel). 2022;14(7):1734. https:\/\/doi.org\/10.3390\/cancers14071734.","journal-title":"Cancers (Basel)"},{"issue":"20","key":"2612_CR23","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"issue":"12","key":"2612_CR24","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"2612_CR25","doi-asserted-by":"publisher","unstructured":"Azanza JR, Mensa J, Barber\u00e1n J, V\u00e1zquez L, P\u00e9rez de Oteyza J, Kwon M, et al. Recommendations on the use of azole antifungals in hematology-oncology patients. Rev Esp Quimioter. 2023;36(3):236\u2013258. https:\/\/doi.org\/10.37201\/req\/013.2023.","DOI":"10.37201\/req\/013.2023"},{"issue":"22","key":"2612_CR26","doi-asserted-by":"publisher","first-page":"5409","DOI":"10.3390\/cancers15225409","volume":"15","author":"A Alsouqi","year":"2023","unstructured":"Alsouqi A, Geramita E, Im A. Treatment of acute myeloid leukemia in older adults. Cancers (Basel). 2023;15(22):5409. https:\/\/doi.org\/10.3390\/cancers15225409.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2612_CR27","first-page":"290","volume":"11","author":"S Mirgh","year":"2021","unstructured":"Mirgh S, Sharma A, Shaikh MRMA, Kadian K, Agrawal N, Khushoo V, et al. Hypomethylating agents + venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country. Am J Blood Res. 2021;11(3):290\u2013302.","journal-title":"Am J Blood Res"},{"issue":"8","key":"2612_CR28","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1080\/10428194.2020.1742908","volume":"61","author":"S Otoukesh","year":"2020","unstructured":"Otoukesh S, Zhang J, Nakamura R, Stein AS, Forman SJ, Marcucci G, et al. The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. Leuk Lymphoma. 2020;61(8):2020\u20133. https:\/\/doi.org\/10.1080\/10428194.2020.1742908.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2612_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/ajh.25859","volume":"95","author":"M Byrne","year":"2020","unstructured":"Byrne M, Danielson N, Sengsayadeth S, Rasche A, Culos K, Gatwood K, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am J Hematol. 2020;95(9):1006\u201314. https:\/\/doi.org\/10.1002\/ajh.25859.","journal-title":"Am J Hematol"},{"issue":"4","key":"2612_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000549","volume":"5","author":"J Feld","year":"2021","unstructured":"Feld J, Tremblay D, Dougherty M, Czaplinska T, Sanchez G, Brady C, et al. Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies. Hemasphere. 2021;5(4): e549. https:\/\/doi.org\/10.1097\/HS9.0000000000000549.","journal-title":"Hemasphere"},{"issue":"1","key":"2612_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-022-01229-z","volume":"15","author":"NJ Short","year":"2022","unstructured":"Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, et al. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022;15(1):12. https:\/\/doi.org\/10.1186\/s13045-022-01229-z.","journal-title":"J Hematol Oncol"},{"issue":"13","key":"2612_CR32","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6(13):3997\u20134005. https:\/\/doi.org\/10.1182\/bloodadvances.2022007265.","journal-title":"Blood Adv"},{"issue":"10","key":"2612_CR33","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3324\/hae-matol.2022.281214","volume":"107","author":"N Gangat","year":"2022","unstructured":"Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, et al. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia. Haematologica. 2022;107(10):2501\u20135. https:\/\/doi.org\/10.3324\/hae-matol.2022.281214.","journal-title":"Haematologica"},{"key":"2612_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106904","volume":"119","author":"AL Chojecki","year":"2022","unstructured":"Chojecki AL, Arnall J, Boselli D, Patel R, Chiad Z, DiSogra KY, et al. Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA\/venetoclax. Leuk Res. 2022;119: 106904. https:\/\/doi.org\/10.1016\/j.leukres.2022.106904.","journal-title":"Leuk Res"},{"issue":"20","key":"2612_CR35","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3(20):2911\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2019000243.","journal-title":"Blood Adv"},{"issue":"4","key":"2612_CR36","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0710.","journal-title":"Cancer Discov"},{"issue":"4","key":"2612_CR37","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00277-024-05646-7","volume":"103","author":"L Zhao","year":"2024","unstructured":"Zhao L, Yang J, Chen M, Xiang X, Ma H, Niu T, et al. Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study. Ann Hematol. 2024;103(4):1197\u2013209. https:\/\/doi.org\/10.1007\/s00277-024-05646-7.","journal-title":"Ann Hematol"},{"issue":"12","key":"2612_CR38","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/ajh.25978","volume":"95","author":"E Morsia","year":"2020","unstructured":"Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95(12):1511\u201321. https:\/\/doi.org\/10.1002\/ajh.25978.","journal-title":"Am J Hematol"},{"key":"2612_CR39","doi-asserted-by":"publisher","unstructured":"Johnson IM, Ilyas R, McCullough K, Al-Kali A, Alkhateeb HB, Begna K, et al. Molecular predictors of response and survival in patients with relapsed\/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy. Blood. 2022;140((Suppl. 1)):3233\u20133234. https:\/\/doi.org\/10.1182\/blood-2022-167967.","DOI":"10.1182\/blood-2022-167967"},{"issue":"386","key":"2612_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078276","volume":"3","author":"O Efthimiou","year":"2024","unstructured":"Efthimiou O, Seo M, Chalkou K, Debray T, Egger M, Salanti G. Developing clinical prediction models: a step-by-step guide. BMJ. 2024;3(386): e078276. https:\/\/doi.org\/10.1136\/bmj-2023-078276.","journal-title":"BMJ"},{"issue":"10","key":"2612_CR41","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/mc.23600","volume":"62","author":"L Zong","year":"2023","unstructured":"Zong L, Yin M, Kong J, Zhang J, Song B, Zhu J, et al. Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients. Mol Carcinog. 2023;62(10):1572\u201384. https:\/\/doi.org\/10.1002\/mc.23600.","journal-title":"Mol Carcinog"},{"issue":"2","key":"2612_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99(2):193\u2013202. https:\/\/doi.org\/10.1002\/ajh.27138.","journal-title":"Am J Hematol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02612-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02612-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02612-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:23:37Z","timestamp":1747754617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02612-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2612"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02612-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from the patient for the publication of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}},{"value":"This study was approved for implementation by the Ethics Committee of the Second Affiliated Hospital of Dalian Medical University (Lot Number: KY2024-183-01).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"831"}}